news

Our latest
Press Releases & Updates

Latest press releases

RetinAI and Retina Consultants of America Join Forces to build the Most Comprehensive U.S.-based Real World Evidence Database in Ophthalmology

RetinAI Medical AG and Retina Consultants of America (RCA) forge a strategic partnership to revolutionize Ophthalmology data. Leveraging RetinAI's advanced AI technologies and RCA's expansive clinic network, this alliance is set to develop the largest Real World Evidence (RWE) U.S.-based database in the field.

RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence

RetinAI Medical AG has announced a partnership with Boehringer Ingelheim to improve patient outcomes in geographic atrophy (GA). RetinAI's AI tools for identifying novel biomarkers will be used to analyze Boehringer Ingelheim's imaging datasets from clinical studies and real-world evidence to identify additional biomarkers and predictors of disease progression. This partnership aims to accelerate the development of novel treatments and enable earlier and more precise diagnosis, contributing to Boehringer Ingelheim's vision of preventing vision loss and blindness caused by retinal diseases.

RetinAI’s AI Algorithms Enrich Clinical Research and Improve Patient Care

RetinAI Medical AG has announced the acceptance of five abstracts for poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) conference taking place from April 23rd to 26th, 2023 in New Orleans. These studies highlight the potential of RetinAI’s Discovery platform and its certified and research use only (RUO) AI models to revolutionize healthcare decisions, improve patient care, help accelerate clinical trials, and drive better decisions for patient management.

RetinAI and Geographic Atrophy (GA) Expert Working Group partner to enable data collaboration and automated analysis of GA biomarkers for CAM using Discovery

RetinAI partnered with the Classification of Atrophy Meeting (CAM) Group in December 2022 to provide RetinAI’s Discovery® platform to the expert working group, consisting of more than 30 members, to facilitate peer-to-peer data collaboration and perform accelerated, automated biomarker analysis of real-world datasets of geographic atrophy (GA) patients. 

Latest updates

124E International Congress de la SFO [MAY'18]

RetinAI had the pleasure to present in the 124e Congrès International de la Société Française d'Ophthalmologie in the session: 'L'impact de l'intelligence artificielle dans la santé visuelle', organised by Optic 2000 in Paris! Wonderful day presenting how AI and machine learning are changing the current paradigm of screening and monitoring of eye diseases.

ARVO 2018 Honolulu - Hawaï [APRIL-MAY'18]

RetinAI is getting ready for the American Research in Vision and Ophthalmology #ARVO2018 in Hawaii! Come to our booth 1039 if you want to learn about how #AI is changing the world of ophthalmic care!

Bilan Magazine TOP 50 Startups in which to invest 2018 [FEBRUARY'18]

RetinAI has been selected as one of the TOP50 Swiss startups in which to invest by the Bilan Magazine. The committee of experts evaluated the progress and projection of hundreds of startups from the Swiss ecosystem and selected the 50 most promising technologies for 2018! Congratulations to the team for this great success.

Read more

5th international Congress OCT Angiography [DECEMBER'17]

RetinAI will be presenting the latest company's developments in this year's edition of the 5th International Congress on OCT Angiography in Rome, on the 15-16th December. Don't forget to come to our session: Unleashing the potential of longitudinal image analysis in Optical Coherence Tomography.

Contact us for more informations! We are happy to hear from you!